Cytogenetic and molecular responses and
β
Hagop Kantarjian; Susan O'Brien; Jianqin Shan; Xuelin Huang; Guillermo Garcia-Ma
π
Article
π
2008
π
John Wiley and Sons
π
English
β 633 KB
## Abstract ## BACKGROUND. Response rates in chronic myeloid leukemia (CML) are now reported based on the cumulative incidence of a singleβtime best response. The study aim was to examine the significance of different response criteria for CML on imatinib therapy. ## METHODS. In all, 276 patient